Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy of Nicotine in Preventing COVID-19 Infection (NICOVID-PREV)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04583410
Recruitment Status : Recruiting
First Posted : October 12, 2020
Last Update Posted : February 17, 2021
Sponsor:
Information provided by (Responsible Party):
Assistance Publique - Hôpitaux de Paris

Brief Summary:

The coronavirus disease (COVID-19) epidemic represents a major therapeutic challenge. The highly contagious severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) and the long duration of the disease have led to a massive influx of patients admitted in health services and intensive care units.

According to current knowledge, there are no treatments that prevent the spread of the infection, especially in exposed populations, or the disease progression to a severe form.

Daily active smokers are infrequent among outpatients or hospitalized patients with COVID-19. Several arguments suggest that nicotine is responsible for this protective effect via the nicotinic acetylcholine receptor (nAChR).

Nicotine may inhibit the penetration and spread of the virus and have a prophylactic effect in COVID-19 infection.

However, the epidemic is progressing throughout French territory and new variants (in particular the "English B1. 1.7 variant of SARS-COV-2") much more contagious run a risk of accelerating the epidemic in the population. The anti-SARS-COV-2 vaccines recently launched (or being evaluated) represent great hope in this health crisis, but trials were only able to show their effectiveness on symptomatic forms of SARS-COV-2 infection. On the one hand, the vaccination compaign for the entire population requires many months,which leaves many unprotected subjects waiting. In addition, there is currently no evidence of a protective role of vaccines against asymptomatic forms of COVID-19 and therefore on SARS-COV-2 transmission. Finally, the nicotine patches may protect people in hight-risk areas/periods until they are vaccinated (if they accept it and are eligible for it) and in the post-vaccination weeks necessary for the effectiveness of the vaccine,which reinforces the importance of evaluating this alternative prevention strategy, in the context of the arrival of vaccines


Condition or disease Intervention/treatment Phase
Covid19 SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere Drug: Nicotine patch Drug: Placebo patch Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 1633 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Efficacy of Nicotine in Preventing COVID-19 Infection
Actual Study Start Date : October 22, 2020
Estimated Primary Completion Date : December 2021
Estimated Study Completion Date : June 2022


Arm Intervention/treatment
Experimental: Nicotine patch Drug: Nicotine patch

NICOPATCHLIB, 7mg/24h Day 1 to day 3 : 3,5 mg/day Day 4 to day 9 : 7 mg/day Day 10 to Day 15 : 10,5 mg/day Day 16 to day 98 : 14 mg/day

Decrease treatment Day 99 to day 105 : 10,5 mg/day Day 106 to day 112 : 7 mg/day Day 113 to Day 119 : 3,5 mg/day


Placebo Comparator: Placebo patch Drug: Placebo patch

PLACEBO OF NICOPATCHLIB, 7mg/24h Day 1 to day 3 : 3,5 mg/day Day 4 to day 9 : 7 mg/day Day 10 to Day 15 : 10,5 mg/day Day 16 to day 98 : 14 mg/day

Decrease treatment Day 99 to day 105 : 10,5 mg/day Day 106 to day 112 : 7 mg/day Day 113 to Day 119 : 3,5 mg/day





Primary Outcome Measures :
  1. SARS-COV2 seroconversion between W0 and W19 after randomization [ Time Frame: Between week 0 and week 19 ]
    This is the proportion of subjects with at least one positive serology between W2 and W19. The time of S19 takes into account a seroconversion delay of 5 weeks in relation to the SARS-CoV2 contamination.


Secondary Outcome Measures :
  1. Proportion of documented symptomatic COVID-19 infection [ Time Frame: Week 8, Week16 ]
  2. SARS-COV2 seroconversion [ Time Frame: Week 16 ]
    This is the proportion of patients with at least one positive serology between W2 and W16.

  3. Asymptomatic COVID-19 infection proportion at week 14 [ Time Frame: Week 14 ]
    Asymptomatic COVID-19 infection is defined as SARS-CoV2 seroconversion at Week 19 without symptoms suggestive of COVID until the end of Week 16 to take in account of the two weeks of incubation period

  4. Proportion of severe COVID-19 infection [ Time Frame: Week 8, Week16 ]
    documented infection (positive SARS-CoV2 PCR test and / or suggestive chest CT scan and / or seroconversion) whose first symptoms appeared before W8 and W16 respectively, and requiring hospitalization or home oxygen therapy, or having resulted in death

  5. Number of sick leaves for a COVID-19 infection [ Time Frame: Week 16 ]
  6. Number of days off during sick leaves for a COVID-19 infection [ Time Frame: Week 16 ]
  7. Proportion of AE, SAE [ Time Frame: From inclusion and week 25 ]
  8. Intensity and frequency of nausea, dizziness, feeling of empty head, headache, vomiting [ Time Frame: Week 25 ]
  9. Proportion of active smoker or active vapers or taking nicotine substitutes documented by examination [ Time Frame: Week 25 ]
  10. Proportion of active smoker or active vapers or taking nicotine substitutes documented by urinary cotinine [ Time Frame: Week 25 ]
  11. Mean score of Desire to smoke defined by French Tobacco Craving scale [ Time Frame: Week 25 ]
  12. Mean score of Withdrawal symptoms scale [ Time Frame: Week 25 ]
  13. Dosage of cotinine in the urine [ Time Frame: Week 8 and 25 ]
  14. Mean score of Fatigue Numeric rating scale [ Time Frame: Week 2, week 8, week 16 ]
  15. Weight [ Time Frame: Week 8, week 16, week 25 ]
  16. Mean score of Hospital anxiety and depression scale [ Time Frame: Week 2, week 8, week 16 ]
  17. Mean score of Insomnia severity scale [ Time Frame: Week 2, week 8, week 16 ]
  18. Positive and negative syndrome scale [ Time Frame: Week 2, week 8, week 16 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Aged 18 or over
  2. May be followed for the duration of the study
  3. Obtaining free, informed and signed consent
  4. Affiliated to a social security scheme or beneficiary of such a scheme (except AME)
  5. Non-smoker and non-vaping (for former smokers or vapers: abstinent for at least 12 months)

Exclusion Criteria:

  1. Symptoms suggestive of COVID-19 on the day of inclusion or in the past 14 days
  2. Documented history of COVID-19 and / or positive SARS-COV2 serology before the day of inclusion
  3. Treatment ongoing with nicotine replacement therapy, varenicline or bupropion within 30 days before inclusion
  4. Known addiction problem to alcohol (defined by AUDIT-C > or = 10) or other substances.
  5. Vaccinated against COVID19 infection.
  6. Contraindications for nicotine patches:

    • pregnant woman (negative pregnancy test on inclusion) or breastfeeding woman
    • lack of effective contraception for women of childbearing potential
    • Generalized skin conditions that can interfere with the use of a transdermal patch
    • stroke or myocardial infarction or acute coronary syndrome for less than 3 months
    • allergy to nicotine or to one of the excipients of the transdermal patch
    • Uncontrolled high blood pressure
    • Unstable or worsening angor
    • Severe cardiac arrhythmia (defined by wearing an automatic implantable defibrillator)
    • Obliterating peripheral arterial disease
    • Known severe heart failure
    • Known severe renal or hepatic impairment,
    • Pheochromocytoma
    • Uncontrolled hyperthyroidism
    • Esophagitis due to gastroesophageal reflux disease or active peptic ulcer

      7 Already included in an interventional trial evaluating a health product 8 Staff under guardianship or curatorship or deprived of their liberty by a judicial or administrative decision 9 Do not have a smartphone


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04583410


Contacts
Layout table for location contacts
Contact: Zahir AMOURA, MD +33142178244 zahir.amoura@aphp.fr
Contact: Florence TUBACH, MD florence.tubach@aphp.fr

Locations
Layout table for location information
France
Centre Hospitalier Gonesse Recruiting
Gonesse, France, 95500
Contact: Isabelle AMOURA, MD       isabelle.amoura@ch-gonesse.fr   
Groupe Hospitalier de la Région de Mulhouse Sud Alsace Not yet recruiting
Mulhouse, France, 68100
Contact: Guylaine LABRO, MD       guylaine.labro@ghrmsa.fr   
Hôpital Pitié Salpêtrière - Service de Médecine Interne Recruiting
Paris, France, 75013
Contact: Zahir AMOURA, MD       zahir.amoura@aphp.fr   
Hôpital Sainte-Anne Not yet recruiting
Paris, France, 75014
Contact: Raphael GAILLARD, MD       r.gaillard@ghu-paris.fr   
Sponsors and Collaborators
Assistance Publique - Hôpitaux de Paris
Investigators
Layout table for investigator information
Principal Investigator: Zahir AMOURA, MD Assistance Publique - Hôpitaux de Paris
Layout table for additonal information
Responsible Party: Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier: NCT04583410    
Other Study ID Numbers: APHP200538
2020-003722-23 ( EudraCT Number )
First Posted: October 12, 2020    Key Record Dates
Last Update Posted: February 17, 2021
Last Verified: February 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Assistance Publique - Hôpitaux de Paris:
Covid19
SARS-COV2
Preventing infection
Additional relevant MeSH terms:
Layout table for MeSH terms
Infections
COVID-19
Severe Acute Respiratory Syndrome
Respiratory Tract Infections
Pneumonia, Viral
Pneumonia
Virus Diseases
Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases
Nicotine
Ganglionic Stimulants
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Nicotinic Agonists
Cholinergic Agonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action